Gotistobart nearly doubles survival in pretreated squamous lung cancer
German biotech company BioNTech (Nasdaq: BNTX) and its US partner OncoC4 have put a firm number on a survival benefit they had been describing in general terms for more than a year, reporting mature overall survival (OS) data from the first stage of their Phase III lung cancer trial.
Patients with metastatic squamous non-small cell lung cancer (NSCLC) treated with gotistobart lived a median of 18.5 months, against 10.0 months for those given the chemotherapy docetaxel. The figures come from the non-pivotal stage 1 of the PRESERVE-003 trial and were presented at the 2026 World Conference on Lung Cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze